

Juan Carlos Garc a-Ca averas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1010899/publications.pdf>

Version: 2024-02-01

33
papers

2,237
citations

331642

21
h-index

414395

32
g-index

35
all docs

35
docs citations

35
times ranked

3994
citing authors

#	ARTICLE	IF	CITATIONS
1	MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. <i>Immunity</i> , 2022, 55, 65-81.e9.	14.3	74
2	SHMT inhibition is effective and synergizes with methotrexate in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2021, 35, 377-388.	7.2	68
3	Reviewing the metabolome coverage provided by LC-MS: Focus on sample preparation and chromatography-A tutorial. <i>Analytica Chimica Acta</i> , 2021, 1147, 38-55.	5.4	40
4	Tumor Microenvironment-Derived Metabolites: A Guide to Find New Metabolic Therapeutic Targets and Biomarkers. <i>Cancers</i> , 2021, 13, 3230.	3.7	17
5	c-MYC Triggers Lipid Remodelling During Early Somatic Cell Reprogramming to Pluripotency. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 2245-2261.	3.8	6
6	CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. <i>Cells</i> , 2021, 10, 2334.	4.1	7
7	Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 595-606.	4.1	39
8	Endothelin-1 Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020, 80, 4224-4232.	0.9	12
9	Chaperone-mediated autophagy regulates the pluripotency of embryonic stem cells. <i>Science</i> , 2020, 369, 397-403.	12.6	60
10	Novel media formulations to enhance Chimeric Antigen Receptor (CAR) T-cell potency and anti-tumor cell function for adoptive immunotherapy. <i>Cytotherapy</i> , 2020, 22, S133.	0.7	3
11	Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. <i>Cell</i> , 2020, 183, 1848-1866.e26.	28.9	347
12	A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway. <i>Nature Chemical Biology</i> , 2020, 16, 731-739.	8.0	101
13	Serine Catabolism Feeds NADH when Respiration Is Impaired. <i>Cell Metabolism</i> , 2020, 31, 809-821.e6.	16.2	118
14	Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 ⁺ T cell stemness and antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 6047-6055.	7.1	128
15	Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. <i>Nature</i> , 2019, 571, 403-407.	27.8	156
16	The Tumor Metabolic Microenvironment: Lessons from Lactate. <i>Cancer Research</i> , 2019, 79, 3155-3162.	0.9	140
17	Sparse N-way partial least squares by L1-penalization. <i>Chemometrics and Intelligent Laboratory Systems</i> , 2019, 185, 85-91.	3.5	7
18	LipidMS: An R Package for Lipid Annotation in Untargeted Liquid Chromatography-Data Independent Acquisition-Mass Spectrometry Lipidomics. <i>Analytical Chemistry</i> , 2019, 91, 836-845.	6.5	33

#	ARTICLE	IF	CITATIONS
19	PPAR β is a nexus controlling alternative activation of macrophages via glutamine metabolism. <i>Genes and Development</i> , 2018, 32, 1035-1044.	5.9	84
20	A lipidomic cell-based assay for studying drug-induced phospholipidosis and steatosis. <i>Electrophoresis</i> , 2017, 38, 2331-2340.	2.4	18
21	RpeakChrom: Novel R package for the automated characterization and optimization of column efficiency in high-performance liquid chromatography analysis. <i>Electrophoresis</i> , 2017, 38, 2985-2995.	2.4	3
22	Liver Transplantation Biomarkers in the Metabolomics Era. <i>Biomarkers in Disease</i> , 2017, , 99-128.	0.1	2
23	A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury. <i>Scientific Reports</i> , 2016, 6, 27239.	3.3	67
24	Extending metabolome coverage for untargeted metabolite profiling of adherent cultured hepatic cells. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 1217-1230.	3.7	32
25	Liver Transplantation Biomarkers in the Metabolomics Era. <i>Biomarkers in Disease</i> , 2016, , 1-29.	0.1	0
26	LC-MS untargeted metabolomic analysis of drug-induced hepatotoxicity in HepG2 cells. <i>Electrophoresis</i> , 2015, 36, 2294-2302.	2.4	32
27	In vitro/in vivo screening of oxidative homeostasis and damage to DNA, protein, and lipids using UPLC/MS-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 5465-5476.	3.7	20
28	Ultra-Performance Liquid Chromatography-Mass Spectrometry Targeted Profiling of Bile Acids: Application to Serum, Liver Tissue, and Cultured Cells of Different Species. <i>Methods in Molecular Biology</i> , 2014, 1198, 233-247.	0.9	8
29	Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction. <i>Journal of Hepatology</i> , 2014, 61, 564-574.	3.7	63
30	Mammalian cell metabolomics: Experimental design and sample preparation. <i>Electrophoresis</i> , 2013, 34, 2762-2775.	2.4	163
31	Targeted profiling of circulating and hepatic bile acids in human, mouse, and rat using a UPLC-MRM-MS-validated method. <i>Journal of Lipid Research</i> , 2012, 53, 2231-2241.	4.2	220
32	Chemometric approaches to improve PLS-DA model outcome for predicting human non-alcoholic fatty liver disease using UPLC-MS as a metabolic profiling tool. <i>Metabolomics</i> , 2012, 8, 86-98.	3.0	54
33	A Comprehensive Untargeted Metabolomic Analysis of Human Steatotic Liver Tissue by RP and HILIC Chromatography Coupled to Mass Spectrometry Reveals Important Metabolic Alterations. <i>Journal of Proteome Research</i> , 2011, 10, 4825-4834.	3.7	114